Achilles Therapeutics (ACHL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Achilles Therapeutics has reported a promising second quarter with a strategic collaboration with Arcturus Therapeutics to develop mRNA cancer vaccines and positive results from Phase I/IIa trials in NSCLC and melanoma. The company has a strong financial position, with $95.1 million to fund operations into 2025. The updates demonstrate the potential of Achilles’ AI-driven precision T cell therapies and the company’s continued progress in oncology.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.
